Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products
Frankfurt am Main, 08.04.2013 Merz Pharma Group ("Merz" or "the Company") today announced that it has withdrawn its non-binding proposal to acquire all of the outstanding common...
Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products
Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products Frankfurt am Main, 08.04.2013 Merz Pharma Group ("Merz" or "the Company") today announced that it has withdrawn its non-binding...
GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
- 208,000 square foot building houses 1,300 employees - and not a single office
PHILADELPHIA, April 6, 2013
GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
- 208,000 square foot building houses 1,300 employees - and not a single office
PHILADELPHIA, April 5, 2013
Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape
Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape PARSIPPANY, N.J. and...
Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
ZUG...
Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc.
Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures
DETROIT, April 4, 2013 /PRNewswire/ -- Amgen Inc.
Roche launches new test for diagnosis and monitoring of thyroid cancer
Roche launches new test for diagnosis and monitoring of thyroid cancer The Elecsys Calcitonin marker expands Roche's portfolio for improved thyroid management Basel, 4 April 2013 Roche (SIX: RO, ROG;...
ARIAD Provides Update on Important Progress Being Made in R&D and Commercial Initiatives
ARIAD Provides Update on Important Progress Being Made in R&D and Commercial Initiatives
ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315
Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
INDIANAPOLIS, April 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financia
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK Issued: Wednesday 3 April 2013, London UK GlaxoSmithKline plc announced today the...
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis Wednesday 3 April 2013, London UK GlaxoSmithKline plc (GSK) today announced the start of a...
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash MONTREAL, April 3, 2013 -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and...
Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit
Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit PARSIPPANY, N.J., April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States...
US District Court rules one PULMICORT RESPULES® (budesonide inhalation suspension) patent invalid and another patent not infringed
US District Court rules one PULMICORT RESPULES® (budesonide inhalation suspension) patent invalid and another patent not infringed Monday, 1 April 2013 AstraZeneca today announced that the United...
Tetragenetics Announces Collaboration with Amgen
Exclusive Research License Of Tetragenetics’ Technology For Surface Antigen Drug Target
Tetragenetics Announces Collaboration with Amgen
Merz Pharma Group Makes Superior Proposal to Acquire Obagi Medical Products
Merz Pharma Group Makes Superior Proposal to Acquire Obagi Medical Products Proposes to Acquire All of Obagi's Outstanding Common Stock for $22 Per Share in Cash Transaction Not Conditioned Upon...
